The American pharmacist Moderna (NASDAQ: MRNA) shoots up in the American market after hours after informing yesterday that it has just launched the first batch of mRNA-1273, its experimental vaccine against the new coronavirus, to begin its clinical trial in humans.
The company, according to a statement, has sent samples of mRNA-1273 to the National Institute of Allergy and Infectious Diseases (NIAID), which belongs to the National Institutes of Health (NIH) for the Phase 1 clinical study.
The company’s manufacturing plant in Norwood (Massachusetts) develops vaccines and therapeutic products. To date, the firm has produced and launched more than 100 lots for clinical trials in humans, according to its statement.
We remember that the US president, Donald Trump, said last night on his Twitter account that “the coronavirus is very controlled in the United States. We are in contact with all the relevant countries ”, and took advantage of their message to make a nod to the Stock Exchange.
